A new clinical trial aims to examine the use of esketamine in addressing postoperative sleep disturbances in postmenopausal women. This study could bring fresh insights for medical professionals seeking improved outcomes in postoperative care, particularly in managing circadian rhythm disorders.
In this article:
- What changed?
- Study overview and objectives
- Potential implications for clinical and regulatory teams
- FAQ
- Conclusion
- Disclaimer
- Announcement details
What changed?
The trial, titled “Effect of Esketamine on Postoperative Sleep in Postmenopausal Women,” has been listed on ClinicalTrials.gov but is not yet recruiting candidates as of January 2026. This investigation, sponsored by Zhuan Zhang, explores esketamine’s potential to alleviate sleep disturbances following surgery, a persistent condition that affects many women, particularly postmenopause.
The trial explicitly focuses on circadian rhythm disorders and postoperative sleep issues, comparing the effects of esketamine to normal saline as a control. This marks a significant opportunity to understand how esketamine—a known treatment for depression—could also influence sleep regulation in a postoperative context.
Study overview and objectives
The primary objective of this trial is to test the safety and efficacy of esketamine for mitigating postoperative sleep disturbances in postmenopausal women. Key focus areas include:
- Study Population: Postmenopausal women experiencing sleep impairments due to surgery.
- Conditions Investigated: Circadian rhythm disorders and associated postoperative complications.
- Interventions: Experimental arm with esketamine vs. the control arm with normal saline.
- Clinical Endpoints: Quality of postoperative sleep, recovery times, and measures of safety and tolerability.
These parameters aim to provide actionable data not only for researchers but also for medical device manufacturers involved in perioperative monitoring solutions. The findings may hold value for regulatory submissions, such as safety profiles and efficacy data linked to pharmacological interventions.
Potential implications for clinical and regulatory teams
Advancements in mitigating postoperative issues such as circadian disruptions could have far-reaching impacts. Medical teams would gain an extended toolkit to customize postoperative care, while regulators could adapt standards to consider esketamine’s role in perioperative settings.
For quality teams, the study also raises relevant questions about how interventions like esketamine should interface with surgical care protocols focused on sleep metrics. Current regulatory pathways for pharmaceutical products addressing circadian and sleep-specific outcomes may require adjustments based on trial results.
This investigation aligns with broader trends across clinical and device markets, emphasizing the integration of pharmacological and non-pharmacological approaches to maximize patient outcomes. Stakeholders should monitor the study’s outcomes closely, given its ability to influence regulatory landscapes and therapeutic strategies in postoperative sleep management.
FAQ
- What is the focus of the trial?
The trial examines the effects of esketamine compared to normal saline on postoperative sleep disturbances in postmenopausal women. - Who is eligible for participation?
Postmenopausal women experiencing postoperative sleep issues linked to circadian rhythm disruption are the intended study population. - What are the planned interventions?
Patients will receive either esketamine or normal saline as part of the trial. - When will the trial begin enrolling participants?
The study is listed as “not yet recruiting” as of January 2026. Updates will be available via ClinicalTrials.gov.
Conclusion
This upcoming clinical trial represents a pivotal exploration of how esketamine could redefine postoperative care for postmenopausal women. By focusing on sleep disturbances regulated by circadian patterns, the study extends broader implications for clinical teams and regulatory frameworks.
Medical and regulatory professionals should monitor developments to incorporate findings into patient care optimizations and regulatory submissions accordingly. Collaboration between sponsors, researchers, and clinical teams will be instrumental.
Disclaimer
This article is intended for informational purposes only and does not provide legal, clinical, or regulatory advice. Readers should consult appropriate professionals for their specific needs.
Announcement details
For full information about the announcement, see the link below.
https://clinicaltrials.gov/study/NCT07315074?term=medical+device